The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy
PHASE4CompletedINTERVENTIONAL
Enrollment
238
Participants
Timeline
Start Date
March 16, 2015
Primary Completion Date
September 8, 2016
Study Completion Date
September 8, 2016
Conditions
Hypertension
Interventions
DRUG
OROSARTAN® 5/160mg
DRUG
CODIOVAN® 160/12.5mg
Trial Locations (1)
Unknown
Gachon University Gil Hospital, Incheon
All Listed Sponsors
lead
Dong-A ST Co., Ltd.
INDUSTRY
NCT02433119 - The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy | Biotech Hunter | Biotech Hunter